公开(公告)号：US11740240B2

公开(公告)日：2023-08-29

申请号：US17379193

申请日：2021-07-19

Applicant: BIO-RAD LABORATORIES, INC.

Inventor： Qian Gao ,  Ravi Kaul ,  Shuxia Zhou ,  Roger P. Walker

IPC: G01N33/569 ,  G01N21/64

CPC classification number: G01N33/56983 ,  G01N21/6428 ,  G01N2021/6439 ,  G01N2333/165

Abstract: The present invention relates to the development of novel immunoassays for the detection of neutralizing antibodies and/or high avidity neutralizing antibodies to SARS-CoV-2 spike protein variants or fragments thereof and, optionally, one or more cytokine in patient samples. Novel multiplex and singleplex immunoassays for the detection of neutralizing antibodies and/or high avidity neutralizing antibodies to SARS-CoV-2 spike protein variants or fragments thereof and, optionally, one or more cytokine in patient samples are also provided.

公开(公告)号：US11808772B2

公开(公告)日：2023-11-07

申请号：US16632404

申请日：2018-07-19

Applicant: BIO-RAD EUROPE GMBH ,  BIO-RAD LABORATORIES, INC.

Inventor： Isabelle Batxelli-Molina ,  Florian Salipante ,  Roger P. Walker ,  John Flanagan ,  Jeannette Fareh-Michiel

IPC: G01N33/68 ,  G16B25/10

CPC classification number: G01N33/6893 ,  G01N33/6869 ,  G16B25/10 ,  G01N2333/521 ,  G01N2333/5421 ,  G01N2333/575 ,  G01N2400/40 ,  G01N2800/085

Abstract: The invention provides a method of diagnosing Non-Alcoholic Steatohepatitis (NASH) and/or the hepatic fibrosis status of a subject, especially a subject afflicted with Non-alcoholic fatty liver disease (NAFLD) or NASH, based on the level of only three or more particular biomarkers. The invention further provides a kit suitable for performing said method and the use of said method and methods of treating patients diagnosed in accordance with the disclosed methods.

公开(公告)号：US20130274125A1

公开(公告)日：2013-10-17

申请号：US13801275

申请日：2013-03-13

Applicant: BIO-RAD LABORATORIES INC.

Inventor： Steven R. Binder ,  Roger P. Walker ,  Michelle L. Delanoy

IPC: G01N33/68

CPC classification number: G01N33/6854 ,  G01N33/564 ,  G01N2800/102

Abstract: Rheumatoid arthritis and other autoimmune diseases are diagnosed by multiplex assays for antibodies to a panel of antigens that includes cyclic citrullinated peptide and at least five members of a list that includes BRAF1 506-525, BRAF2 656-675, Vimentin (protein) citrullinated, Vimentin 415-433 cit cyclic, Vimentin 58-77 cit3 cyclic, Clusterin 231-250 cit sm1 cyclic, Fibrinogen A 556-575 cit sm cyclic, Fibrinogen A 616-635 cit sm cyclic, Histones2A H2A/a 1-20 cit sm2 cyclic, Filaggrin 48-65 cit2v1 cyclic, BRAF (catalytic domain from v raf murine sarcoma viral oncogene homologue B1, amino acids 416-766).

Abstract translation: 类风湿性关节炎和其他自身免疫性疾病通过多种测定法诊断，用于抗一组抗原的抗体，包括环瓜氨酸肽和至少五个列表的成员，其中包括BRAF1 506-525，BRAF2 656-675，波形蛋白（蛋白质）瓜氨酸化，波形蛋白 波形蛋白58-77 cit3环状，Clusterin 231-250 cit sm1环状，纤维蛋白原A 556-575 cit sm cyclic，纤维蛋白原A 616-635 cit sm cyclic，Histones2A H2A / a 1-20 cit sm2 cyclic， 丝胶蛋白48-65 cit2v1环状，BRAF（来自v raf鼠肉瘤病毒致癌基因同系物B1的催化结构域，氨基酸416-766）。